Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements
Build a preferred supplier network that provides traceability documentation and COAs consistently
For most users, yes
Your doctor can help determine if a sleep disorder, such as obstructive sleep apnea (OSA), is preventing you from getting the quality sleep that you need
German J, Cordioli M, Tozzo V, Urbut S, Arumae K, Smit RAJ, et al
& Horton, J